Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.735 USD | -1.42% | -6.22% | +20.49% |
04-23 | Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment | CI |
04-10 | Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University | MT |
Business Summary
Number of employees: 3
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | 0.00% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | 0.00% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 12/07/10 |
Daniel Ryweck
DFI | Director of Finance/CFO | 59 | 26/09/22 |
James Kuo
CTO | Chief Tech/Sci/R&D Officer | 58 | 31/08/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 12/07/10 |
Wayne Linsley
BRD | Director/Board Member | 67 | 15/01/20 |
Kevin Muñoz
BRD | Director/Board Member | 46 | 30/09/20 |
Jeff Pavell
BRD | Director/Board Member | 57 | 26/09/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,096,489 | 2,663,202 ( 86.01 %) | 252,855 ( 8.166 %) | 86.01 % |
Company contact information
Sector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.49% | 5M | |
-2.61% | 88.47B | |
+3.55% | 40.71B | |
-13.92% | 32.43B | |
+55.89% | 24.28B | |
-16.00% | 15.52B | |
-41.29% | 12.17B | |
-15.40% | 12.01B | |
-11.75% | 12B | |
+7.87% | 8.87B |
- Stock Market
- Equities
- SILO Stock
- Company Silo Pharma, Inc.